98 related articles for article (PubMed ID: 30306310)
1. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease.
Pieralli A; Bianchi C; Auzzi N; Fallani MG; Bussani C; Fambrini M; Cariti G; Scarselli G; Petraglia F; Ghelardi A
Arch Gynecol Obstet; 2018 Dec; 298(6):1205-1210. PubMed ID: 30306310
[TBL] [Abstract][Full Text] [Related]
2. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.
Coskuner ER; Ozkan TA; Karakose A; Dillioglugil O; Cevik I
J Sex Med; 2014 Nov; 11(11):2785-91. PubMed ID: 25124237
[TBL] [Abstract][Full Text] [Related]
3. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
4. Knowledge, attitudes, practices and barriers towards HPV vaccination among nurses in Turkey: a longitudinal study.
Yanikkerem E; Koker G
Asian Pac J Cancer Prev; 2014; 15(18):7693-702. PubMed ID: 25292048
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
6. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta.
Kim J; Bell C; Sun M; Kliewer G; Xu L; McInerney M; Svenson LW; Yang H
CMAJ; 2016 Sep; 188(12):E281-E288. PubMed ID: 27378467
[TBL] [Abstract][Full Text] [Related]
7. Human Papillomavirus Vaccination Among Adults and Children in 5 US States.
Du P; Camacho F; McCall-Hosenfeld J; Lengerich E; Meyers CM; Christensen ND
J Public Health Manag Pract; 2015; 21(6):573-83. PubMed ID: 26035648
[TBL] [Abstract][Full Text] [Related]
8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
9. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination.
Bhatla N; Lal N; Bao YP; Ng T; Qiao YL
Vaccine; 2008 Jun; 26(23):2811-7. PubMed ID: 18450340
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPV infection and current status of cervical cancer prevention in Greece: final results of the LYSISTRATA cross-sectional study.
Agorastos T; Chatzistamatiou K; Zafrakas M; Siamanta V; Katsamagkas T; Constantinidis TC; Lampropoulos AF;
Eur J Cancer Prev; 2014 Sep; 23(5):425-31. PubMed ID: 24977385
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine.
Igidbashian S; Boveri S; Bottari F; Vidal Urbinati A; Preti E; Casadio C; Landoni F; Sideri M; Sandri MT
J Low Genit Tract Dis; 2017 Jan; 21(1):4-8. PubMed ID: 27755229
[TBL] [Abstract][Full Text] [Related]
15. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
18. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
19. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
20. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
